Zacks Research Has Positive Outlook of Surmodics Q2 Earnings

Surmodics, Inc. (NASDAQ:SRDX) – Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for Surmodics in a research note issued on Tuesday, January 28th. Zacks Research analyst D. Dey now forecasts that the company will post earnings of ($0.05) per share for the quarter, up from their prior estimate of ($0.08). The consensus estimate for Surmodics’ current full-year earnings is $0.19 per share. Zacks Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.21 EPS and Q3 2026 earnings at $0.20 EPS.

SRDX has been the subject of several other research reports. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research note on Thursday. StockNews.com initiated coverage on shares of Surmodics in a research report on Sunday, January 26th. They issued a “hold” rating on the stock. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $50.00.

Surmodics Trading Down 4.1 %

NASDAQ SRDX opened at $34.04 on Friday. The firm has a market cap of $486.43 million, a PE ratio of -42.02 and a beta of 1.21. Surmodics has a one year low of $25.17 and a one year high of $42.44. The firm’s fifty day moving average is $38.70 and its two-hundred day moving average is $39.15. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.96.

Surmodics (NASDAQ:SRDX) last posted its earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.04. Surmodics had a negative return on equity of 3.79% and a negative net margin of 9.15%.

Insider Activity

In other news, CFO Timothy J. Arens sold 7,009 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total value of $276,434.96. Following the sale, the chief financial officer now owns 70,350 shares of the company’s stock, valued at approximately $2,774,604. The trade was a 9.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.90% of the company’s stock.

Hedge Funds Weigh In On Surmodics

Several hedge funds have recently made changes to their positions in the business. New York State Common Retirement Fund raised its holdings in shares of Surmodics by 12.4% during the fourth quarter. New York State Common Retirement Fund now owns 19,544 shares of the company’s stock valued at $774,000 after acquiring an additional 2,162 shares during the period. Principal Financial Group Inc. increased its stake in shares of Surmodics by 17.5% in the fourth quarter. Principal Financial Group Inc. now owns 36,061 shares of the company’s stock worth $1,428,000 after purchasing an additional 5,365 shares during the period. Rhumbline Advisers raised its stake in Surmodics by 4.4% during the 4th quarter. Rhumbline Advisers now owns 20,250 shares of the company’s stock valued at $802,000 after purchasing an additional 861 shares during the last quarter. R Squared Ltd bought a new stake in shares of Surmodics in the 4th quarter worth approximately $55,000. Finally, SG Americas Securities LLC raised its stake in shares of Surmodics by 22.1% in the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock valued at $275,000 after buying an additional 1,255 shares in the last quarter. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).